At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 322 enrolled
Drug / intervention
Rifaximindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label Trial to Evaluate the Long-Term Safety and Tolerability of Rifaximin 550 mg BID in Subjects With a History of Hepatic Encephalopathy
In Brief
A Phase 3 clinical trial evaluating Rifaximin for Hepatic Encephalopathy. Completed, enrolled 322 participants across 35 sites in 2 countries.
Detailed Summary
This study will look at the safety of a drug used in participants who have had hepatic encephalopathy (HE) in the past.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Encephalopathy
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMay 2008
Primary CompletionDec 2010
TodayJul 2026
First PostedMay 30, 2008
Enrollment StartMar 7, 2007
Primary CompletionDec 8, 2010
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.1 years ago
Interventions
Rifaximindrug
Oral